

## Why invest in TCUS?

- Designed for outperformance over traditional broad indices
- Seeking concentrated US equity exposure
- Delivers a disciplined, rules-based portfolio construction
- Rebalances monthly to respond to current market conditions
- Are comfortable with a medium level of risk

## Fund Details

Ticker	TCUS
Base Currency	CAD
Exchange	TSX
CUSIP	89270D107
Mgmt. Fee	0.75%
MER*	-
Current Market Price	\$19.39
Distribution Frequency	Annual
Inception Date	March 10, 2026

\*Management Expense Ratio (MER) is not available until after the fund's fiscal year end

## Fund Characteristics

Net Assets (MM)	\$2.42
Current NAV	\$19.34
Numbers of Securities	50
Shares Outstanding	125,000
Index	Solactive TC Quant US 50 Index
Index Code	STCQUSCN

## Risk Rating

Low	Low to Medium	Medium	Medium to High	High
-----	---------------	--------	----------------	------

## Portfolio Strategy

TCUS seeks to replicate, to the extent possible, the performance of the Solactive TC Quant US 50 Index, before fees and expenses. Built on Trading Central SA's proprietary TC Quantamental Rating®, the TC Quant Indices provide systematic exposure to 50 high-scoring companies, translating Trading Central SA's data-driven research into investable benchmarks.


## Index Information

The Solactive TC Quant US 50 Index is an equal weight index that incorporates the best U.S. companies built on Trading Central SA's proprietary TC Quantamental Rating® process, providing systematic hypothetical exposure to 50 high-scoring companies. Securities are assigned factor scores based on value, growth, quality, momentum, and income indicators.

## Fund Performance

Returns are not available as this ETF has less than one year's performance data.

## Sector Allocation



## Top Holdings

Adeia Inc	2.16%
SkyWater Technology Inc	2.15%
ZoomInfo Technologies Inc	2.13%
GigaCloud Technology Inc	2.13%
Zoom Communications Inc	2.12%
Encore Capital Group Inc	2.12%
Envista Holdings Corp	2.11%
Diebold Nixdorf Inc	2.10%
Millicom International Cellular	2.08%
Arrowhead Pharmaceuticals Inc	2.07%

This material is for informational purposes only. This material is not intended to be relied upon as research, investment, or tax advice and is not an implied or express recommendation, offer or solicitation to buy or sell any security or to adopt any particular investment or portfolio strategy. Any views and opinions expressed do not take into account the particular investment objectives, needs, restrictions and circumstances of a specific investor and, thus, should not be used as the basis of any specific investment recommendation. Investors should consult a financial and/or tax advisor for financial and/or tax information applicable to their specific situation.

The indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns.

All monetary figures are expressed in Canadian dollars unless otherwise noted.

All data contained herein is provided "as is" and LongPoint makes no representation or warranty of any kind, either express or implied, with respect to such data, the timeliness thereof, the results to be obtained by the use thereof or any other matter. LongPoint expressly disclaims any and all implied warranties, including without limitation, warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose.